-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 15, 2021, the "White Paper on the Survey of the Awareness and Visiting Rates of Preclinical Patients with Alzheimer's Disease (AD) in China" (hereinafter referred to as the "White Paper") was publicly released to the whole society
.
This survey was initiated by Professor Han Ying from the Department of Neurology, Xuanwu Hospital of Capital Medical University, and 180 hospitals from the National Geriatrics Clinical Medicine Research Center (Xuanwu Hospital)-China AD Preclinical Alliance participated enthusiastically, and expanded the research group with the help of the Internet platform
.
Yimaitong was fortunate to interview the initiator of this survey, Professor Han Ying, to explain the knowledge points about Alzheimer's disease for us.
This article is organized as follows
.
Yimaitong organizes reports, please do not reprint without authorization
.
Yimaitong: The "White Paper" survey shows that the respondents' awareness of AD and AD pre-clinical subjective cognitive decline (SCD) is not low, but the rate of active consultation is low.
What is the reason? Professor Han Ying, most people do not really understand AD, but have a preliminary understanding of AD through some film and television works and related articles on WeChat public accounts, but in fact, they don’t know how much damage the late AD causes to individuals, so they There are various reasons not to go to the hospital for treatment, such as "recent work or life pressure, it will be fine after a while; or usually too busy at work, no time or think that the symptoms are very light now, there should be no major problems
.
"
Because the incubation period of AD is as long as 20 years, the patient is no different from normal people during the incubation period.
When the patient has obvious clinical symptoms and enters the stage of mild cognitive impairment, most people will not realize that this is a pathological change.
It is normal to mistakenly think that forgetfulness is due to old age
.
Usually most people in China realize that forgetfulness is a pathological condition, and when they think of going to the hospital, more than 80% have reached the stage of moderate to severe dementia
.
Yimaitong: As the aging process continues to accelerate, the incidence of AD is increasing year by year.
Coupled with insufficient cognition, the best time for diagnosis and treatment is often delayed.
Therefore, the popularization of AD science for the public is imminent
.
In order to enhance the public's awareness and attention to early AD, how to better conduct AD science? Only when Professor Han Ying conducts extensive and continuous publicity through multiple channels and multiple methods can more people understand AD
.
Because of the previous classic drugs for the treatment of AD, such as cholinesterase inhibitors and NMDA receptor antagonists, these two drugs can neither prevent nor reverse the course of AD.
This has caused a misunderstanding that AD is a kind of A disease that can neither be prevented nor treated
.
With the advancement of science and technology, it is now possible to diagnose AD in the pre-clinical stage
.
Since the National Institute of Aging (NIA) AD Association published the latest biological standards for AD diagnosis in 2018, as long as amyloid is positive, it means that there is AD pathological change and enters the AD continuous disease spectrum
.
Without clinical symptoms, it can be diagnosed as preclinical AD, and the entire course of AD is divided into 6 stages
.
In the two preclinical stages, it can be as long as 20 years
.
The third stage after the preclinical stage, that is, the stage of mild cognitive impairment can be as long as 3 years
.
Without intervention, the stages of mild cognitive impairment to mild dementia (stage 4), moderate dementia (stage 5), and severe dementia (stage 6) can be as long as 1-3 years, respectively
.
With the advancement of technology, AD diagnosis and treatment can be advanced to the pre-clinical stage
.
The domestically produced original research drug Mannote Sodium, which was launched in December 2019, and Aducanumab, a disease-modifying drug for amyloid-targeted treatment of AD approved by the U.
S.
FDA on June 7, 2021, can block starch in the preclinical stage.
The deposition of protein-like proteins in the cerebral cortex, thereby blocking the course of AD, may transform AD from an incurable disease to a preventable and controllable chronic disease similar to diabetes and high blood pressure
.
Lifelong maintenance in the preclinical stage of dementia does not progress, maintain the quality of life of the patient, and reduce the burden of the caregiver in the future.
All implementation of this requires introspection and self-knowledge of patients in the preclinical stage of AD.
Only early consultation can prevent the progression of the disease in the preclinical stage.
.
Brain cells cannot be regenerated.
In the early stage of the disease, the reserve of cognitive function in the brain can compensate
.
However, when the loss of brain cells exceeds 50%, it will be decompensated, and clinical symptoms will appear, causing the loss of part of the brain function
.
The lost brain function will not be restored.
The current treatment of AD is equivalent to pressing the "pause button
.
"
The earlier the "pause button" is pressed, the greater the number of surviving brain cells, the better the preservation of brain cell function, and the better the prognosis for the patient
.
Yimaitong: Why is it said that early detection, early diagnosis, and early treatment are the only way to prevent and control AD? According to Professor Han Ying's "World Alzheimer's Disease Report 2018", every 3 seconds, a new patient with dementia will be added globally, and about 60-70% of them suffer from AD
.
AD has become the fifth leading cause of death in the world
.
In China, there are currently about 10 million people with AD dementia.
It is estimated that by 2050, there will be more than 40 million people with AD dementia in China
.
Because the dementia stage is irreversible, people lose the best time for diagnosis and treatment at this stage
.
In order to advance the prevention and treatment of AD, the key to prevention and treatment of AD lies in early detection, early diagnosis and early treatment
.
Prof.
Ying Han, Chief Physician, Professor, and Doctoral Supervisor, Department of Neurology, Xuanwu Hospital, Capital Medical University, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases (Xuanwu Hospital)-Chairman of China AD Preclinical Alliance, Beijing Cognitive Neuroscience Society 1st Session Chairman, Xuanwu Hospital, Director of the International Collaborative Research Center for Neuropsychiatric Diseases, Chinese Journal of Neurology and other domestic and foreign academic journals, editors and reviewers of many academic journals at home and abroad, National Natural Science First Review Expert, National Natural Science Foundation Key Project Host, published 143 papers in academic journals at home and abroad
.
This survey was initiated by Professor Han Ying from the Department of Neurology, Xuanwu Hospital of Capital Medical University, and 180 hospitals from the National Geriatrics Clinical Medicine Research Center (Xuanwu Hospital)-China AD Preclinical Alliance participated enthusiastically, and expanded the research group with the help of the Internet platform
.
Yimaitong was fortunate to interview the initiator of this survey, Professor Han Ying, to explain the knowledge points about Alzheimer's disease for us.
This article is organized as follows
.
Yimaitong organizes reports, please do not reprint without authorization
.
Yimaitong: The "White Paper" survey shows that the respondents' awareness of AD and AD pre-clinical subjective cognitive decline (SCD) is not low, but the rate of active consultation is low.
What is the reason? Professor Han Ying, most people do not really understand AD, but have a preliminary understanding of AD through some film and television works and related articles on WeChat public accounts, but in fact, they don’t know how much damage the late AD causes to individuals, so they There are various reasons not to go to the hospital for treatment, such as "recent work or life pressure, it will be fine after a while; or usually too busy at work, no time or think that the symptoms are very light now, there should be no major problems
.
"
Because the incubation period of AD is as long as 20 years, the patient is no different from normal people during the incubation period.
When the patient has obvious clinical symptoms and enters the stage of mild cognitive impairment, most people will not realize that this is a pathological change.
It is normal to mistakenly think that forgetfulness is due to old age
.
Usually most people in China realize that forgetfulness is a pathological condition, and when they think of going to the hospital, more than 80% have reached the stage of moderate to severe dementia
.
Yimaitong: As the aging process continues to accelerate, the incidence of AD is increasing year by year.
Coupled with insufficient cognition, the best time for diagnosis and treatment is often delayed.
Therefore, the popularization of AD science for the public is imminent
.
In order to enhance the public's awareness and attention to early AD, how to better conduct AD science? Only when Professor Han Ying conducts extensive and continuous publicity through multiple channels and multiple methods can more people understand AD
.
Because of the previous classic drugs for the treatment of AD, such as cholinesterase inhibitors and NMDA receptor antagonists, these two drugs can neither prevent nor reverse the course of AD.
This has caused a misunderstanding that AD is a kind of A disease that can neither be prevented nor treated
.
With the advancement of science and technology, it is now possible to diagnose AD in the pre-clinical stage
.
Since the National Institute of Aging (NIA) AD Association published the latest biological standards for AD diagnosis in 2018, as long as amyloid is positive, it means that there is AD pathological change and enters the AD continuous disease spectrum
.
Without clinical symptoms, it can be diagnosed as preclinical AD, and the entire course of AD is divided into 6 stages
.
In the two preclinical stages, it can be as long as 20 years
.
The third stage after the preclinical stage, that is, the stage of mild cognitive impairment can be as long as 3 years
.
Without intervention, the stages of mild cognitive impairment to mild dementia (stage 4), moderate dementia (stage 5), and severe dementia (stage 6) can be as long as 1-3 years, respectively
.
With the advancement of technology, AD diagnosis and treatment can be advanced to the pre-clinical stage
.
The domestically produced original research drug Mannote Sodium, which was launched in December 2019, and Aducanumab, a disease-modifying drug for amyloid-targeted treatment of AD approved by the U.
S.
FDA on June 7, 2021, can block starch in the preclinical stage.
The deposition of protein-like proteins in the cerebral cortex, thereby blocking the course of AD, may transform AD from an incurable disease to a preventable and controllable chronic disease similar to diabetes and high blood pressure
.
Lifelong maintenance in the preclinical stage of dementia does not progress, maintain the quality of life of the patient, and reduce the burden of the caregiver in the future.
All implementation of this requires introspection and self-knowledge of patients in the preclinical stage of AD.
Only early consultation can prevent the progression of the disease in the preclinical stage.
.
Brain cells cannot be regenerated.
In the early stage of the disease, the reserve of cognitive function in the brain can compensate
.
However, when the loss of brain cells exceeds 50%, it will be decompensated, and clinical symptoms will appear, causing the loss of part of the brain function
.
The lost brain function will not be restored.
The current treatment of AD is equivalent to pressing the "pause button
.
"
The earlier the "pause button" is pressed, the greater the number of surviving brain cells, the better the preservation of brain cell function, and the better the prognosis for the patient
.
Yimaitong: Why is it said that early detection, early diagnosis, and early treatment are the only way to prevent and control AD? According to Professor Han Ying's "World Alzheimer's Disease Report 2018", every 3 seconds, a new patient with dementia will be added globally, and about 60-70% of them suffer from AD
.
AD has become the fifth leading cause of death in the world
.
In China, there are currently about 10 million people with AD dementia.
It is estimated that by 2050, there will be more than 40 million people with AD dementia in China
.
Because the dementia stage is irreversible, people lose the best time for diagnosis and treatment at this stage
.
In order to advance the prevention and treatment of AD, the key to prevention and treatment of AD lies in early detection, early diagnosis and early treatment
.
Prof.
Ying Han, Chief Physician, Professor, and Doctoral Supervisor, Department of Neurology, Xuanwu Hospital, Capital Medical University, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases (Xuanwu Hospital)-Chairman of China AD Preclinical Alliance, Beijing Cognitive Neuroscience Society 1st Session Chairman, Xuanwu Hospital, Director of the International Collaborative Research Center for Neuropsychiatric Diseases, Chinese Journal of Neurology and other domestic and foreign academic journals, editors and reviewers of many academic journals at home and abroad, National Natural Science First Review Expert, National Natural Science Foundation Key Project Host, published 143 papers in academic journals at home and abroad
